Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)4.69
  • Today's Change0.04 / 0.86%
  • Shares traded51.76m
  • 1 Year change-20.10%
  • Beta0.5666
Data delayed at least 15 minutes, as of Sep 19 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments13,06813,79610,703
Total Receivables, Net9,8416,8366,549
Total Inventory3,1392,5552,480
Prepaid expenses------
Other current assets, total697770604
Total current assets26,74523,95720,337
Property, plant & equipment, net11,64310,9779,564
Goodwill, net235235150
Intangibles, net2,1991,908468
Long term investments4,6553,7833,356
Note receivable - long term--0254
Other long term assets619797570
Total assets46,28241,77034,742
LIABILITIES
Accounts payable2,4731,7031,481
Accrued expenses842728519
Notes payable/short-term debt000
Current portion long-term debt/capital leases60029638
Other current liabilities, total6,2686,2315,187
Total current liabilities10,1838,9587,226
Total long term debt10728756
Total debt70758394
Deferred income tax575612381
Minority interest1,8151,444842
Other liabilities, total400271250
Total liabilities13,07911,5728,755
SHAREHOLDERS EQUITY
Common stock10,89910,89910,899
Additional paid-in capital39119747
Retained earnings (accumulated deficit)22,22519,16315,155
Treasury stock - common(316)(84)(86)
Unrealized gain (loss)------
Other equity, total4.5022(28)
Total equity33,20330,19825,987
Total liabilities & shareholders' equity46,28241,77034,742
Total common shares outstanding11,90311,93311,950
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.